Insurer advocacy group AHIP has praised the Centers for Medicare and Medicaid Services for its decision to have Medicare cover an Alzheimer’s drug only for beneficiaries in clinical trials, agreeing with the federal agency that more evidence is needed on Aduhelm and other drugs of its ilk.
AHIP lauds CMS decision on Alzheimer’s drug Aduhelm
